Search clinical trials for: XLRP RPGR

Total 15 results

Beacon Therapeutics

Recruiting

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

X-Linked Retinitis Pigmentosa

United States
Janssen Research & Development, LLC

Active, not recruiting

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

X-Linked Retinitis Pigmentosa

United States, United Kingdom
Beacon Therapeutics

Active, not recruiting

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

X-Linked Retinitis Pigmentosa

United States
Beacon Therapeutics

Enrolling by invitation

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

X-Linked Retinitis Pigmentosa

United States
Beacon Therapeutics

Active, not recruiting

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (HORIZON)

X-Linked Retinitis Pigmentosa

United States
Biogen

Completed

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS)

X-Linked Retinitis Pigmentosa

United States, United Kingdom
NightstaRx Ltd, a Biogen Company

Completed

Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS)

X-Linked Retinitis Pigmentosa

United States, France, United Kingdom, Finland, Netherlands, Germany, Canada
Applied Genetic Technologies Corp

Completed

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

X-Linked Retinitis Pigmentosa

United States
MeiraGTx UK II Ltd
Syne Qua Non Limited; Bionical Emas

Completed

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)

X-Linked Retinitis Pigmentosa

United Kingdom, United States
Frontera Therapeutics
Peking Union Medical College Hospital; Eye & ENT Hospital of Fudan University; Henan Provincial People's Hospital

Recruiting

Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

X-Linked Retinitis Pigmentosa

China
Janssen Research & Development, LLC
Janssen Research & Development, LLC

Active, not recruiting

Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

X-Linked Retinitis Pigmentosa

Belgium, Canada, United States, Israel, United Kingdom, Spain, Denmark, France, Italy, Netherlands, Switzerland
Janssen Research & Development, LLC
Janssen Research & Development, LLC

Active, not recruiting

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

X-Linked Retinitis Pigmentosa

United States, Canada, Israel, United Kingdom, Spain, Denmark, France, Belgium, Italy, Netherlands, Switzerland
4D Molecular Therapeutics

Active, not recruiting

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

X-Linked Retinitis Pigmentosa

United States
NightstaRx Ltd, a Biogen Company

Enrolling by invitation

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa (SOLSTICE)

Choroideremia | X-Linked Retinitis Pigmentosa

United States, United Kingdom, Netherlands, Germany, France, Brazil, Canada, Denmark, Finland
MeiraGTx UK II Ltd
Janssen, LP

Active, not recruiting

Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

Retinitis Pigmentosa

United States, United Kingdom, Canada

Search clinical trials for: XLRP RPGR

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations